Inventor
SCHLINGENSIEPEN KARL-HERMANN
DE14 patents
⚠️ This page may combine multiple inventors who share the name “SCHLINGENSIEPEN KARL-HERMANN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
BIOGNOSTIK GES
5 patentsUS6455689B1Sep 24, 2002
Antisense-oligonucleotides for transforming growth factor-β (TGF-β)
BIOGNOSTIK GES49 citations92
US7667027B2Feb 23, 2010
Antisense-oligonucleotides for the treatment of immuno-suppressive effects of transforming growth factor-β (TGF-β)
BIOGNOSTIK GES15 citations87
US6972171B1Dec 6, 2005
Antisense oligonucleotide preparation method
BIOGNOSTIK GES14 citations82
US7563778B2Jul 21, 2009
Antisense oligonucleotide preparation method
BIOGNOSTIK GES2 citations61
US7326783B2Feb 5, 2008
Pharmaceutical composition comprising antisense-nucleic acid for prevention and/or treatment of neuronal injury, degeneration and cell death and for the treatment of neoplasms
BIOGNOSTIK GES0 citations45
SCHLINGENSIEPEN KARL-HERMANN
5 patentsUS8476246B2Jul 2, 2013
Combination of a chemotherapeutic agent and an inhibitor of the TGF-beta system
SCHLINGENSIEPEN KARL-HERMANN11 citations77
US8629117B2Jan 14, 2014
Method for stimulating the immune system
SCHLINGENSIEPEN KARL-HERMANN2 citations60
US8097597B2Jan 17, 2012
Use of low doses of oligonucleotides antisense to TGF-β genes in the treatment of brain tumors
SCHLINGENSIEPEN KARL-HERMANN2 citations60
US8822425B2Sep 2, 2014
Dosage of oligonucleotides suitable for the treatment of tumors
SCHLINGENSIEPEN KARL-HERMANN2 citations49
US8703729B2Apr 22, 2014
Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene
SCHLINGENSIEPEN KARL-HERMANN1 citations49